Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02019277
Registration number
NCT02019277
Ethics application status
Date submitted
18/12/2013
Date registered
24/12/2013
Date last updated
13/09/2018
Titles & IDs
Public title
A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
Query!
Scientific title
An Open-label, Multicentre, Phase IIIb Study With Intravenous Administration of Pertuzumab, Subcutaneous Trastuzumab, and a Taxane in Patients With HER2-positive Metastatic Breast Cancer
Query!
Secondary ID [1]
0
0
ML28784
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
SAPPHIRE
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Breast Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Docetaxel
Treatment: Drugs - Nab-paclitaxel
Treatment: Drugs - Paclitaxel
Treatment: Drugs - Pertuzumab
Treatment: Drugs - Trastuzumab
Experimental: Trastuzumab SC, Pertuzumab, and Taxane - Participants will receive pertuzumab, trastuzumab and a taxane (docetaxel, paclitaxel or nab-paclitaxel) once every 3 weeks (21-day cycles). Choice of taxane will be at the discretion of the investigator and administered per routine clinical practices and local prescribing instructions.
Treatment: Drugs: Docetaxel
Dosing regimen to be determined by the investigator, routine clinical practices.
Treatment: Drugs: Nab-paclitaxel
Dosing regimen to be determined by the investigator, routine clinical practices.
Treatment: Drugs: Paclitaxel
Dosing regimen to be determined by the investigator, routine clinical practices.
Treatment: Drugs: Pertuzumab
Pertuzumab will be administered on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg as an IV infusion every 3 weeks.
Treatment: Drugs: Trastuzumab
Trastuzumab will be administered at a fixed dose of 600 mg SC every 3 weeks.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants With Adverse Events (AEs) and Serious AEs
Query!
Assessment method [1]
0
0
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Percentage of participants with AEs and SAEs was reported. AEs included both SAEs and non-SAEs. The 95% confidence interval (CI) was computed using Clopper-Pearson method.
Query!
Timepoint [1]
0
0
Baseline up to 28 days after last study drug administration (up to 36 months)
Query!
Primary outcome [2]
0
0
Percentage of Participants With AEs by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0 Intensity Grades
Query!
Assessment method [2]
0
0
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Intensity of AEs were graded according to NCI CTCAE version 4.0 on a 5-point scale: Grade 1=Mild, intervention not indicated; Grade 2=Moderate, local or noninvasive intervention indicated; Grade 3=Severe or medically significant but not immediately life-threatening; Grade 4= Life-threatening consequences, urgent intervention indicated; and Grade 5=Death related to AE. Percentage of participants with AEs by maximum severity grades was reported.
Query!
Timepoint [2]
0
0
Baseline up to 28 days after last study drug administration (up to 36 months)
Query!
Primary outcome [3]
0
0
Percentage of Participants With AEs Leading to Premature Discontinuation of Investigational Medicinal Products (IMPs)
Query!
Assessment method [3]
0
0
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Percentage of participants with AEs leading to premature discontinuation of IMPs (pertuzumab and trastuzumab) was reported. AEs included both SAEs and non-SAEs. The 95% CI was computed using Clopper-Pearson method.
Query!
Timepoint [3]
0
0
Baseline up to 28 days after last study drug administration (up to 36 months)
Query!
Primary outcome [4]
0
0
Percentage of Participants With AEs of Suspected Cardiac Origin, by New York Heart Association Classification (NYHA)
Query!
Assessment method [4]
0
0
NYHA functional classification includes: Class I (no limitation in physical activity; ordinary physical activity does not cause fatigue, breathlessness or palpitation), Class II (slight limitation of physical activity; ordinary physical activity results in fatigue, palpitation, breathlessness or angina pectoris), Class III (marked limitation of physical activity; less than ordinary activity will lead to symptomatically 'moderate' heart failure) and Class IV (inability to carry out any physical activity without discomfort; symptoms of congestive cardiac failure are present even at rest). Percentage of participants with AEs suspected to be of cardiac origin by maximum NYHA classification was reported.
Query!
Timepoint [4]
0
0
Baseline up to 28 days after last study drug administration (up to 36 months)
Query!
Primary outcome [5]
0
0
Percentage of Participants With Left Ventricular Ejection Fraction (LVEF) Below 50%
Query!
Assessment method [5]
0
0
LVEF was assessed using echocardiography (ECHO) or multiple-gated acquisition (MUGA) scans. Percentage of participants with LVEF below 50% at any time during the study was reported.
Query!
Timepoint [5]
0
0
Baseline up to 28 days after last study drug administration (up to 36 months)
Query!
Secondary outcome [1]
0
0
Percentage of Participants With Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Query!
Assessment method [1]
0
0
BOR was defined as a confirmed CR or PR. All measurable lesions up to a maximum of 2 lesions per organ and 5 in total were identified as target lesions (TLs) and recorded at baseline. A sum of the diameters (longest for non-nodal lesions, short axis [SA] for nodal lesions) for all TLs was calculated as baseline sum of diameters (SD). All other lesions (or sites of disease) were identified as non-TLs and were recorded at baseline. CR was defined as the disappearance of all TLs and SA reduction to less than (<) 10 millimeter (mm) for nodal TLs/ non-TLs. PR was defined as greater than or equal to (>/=) 30% decrease in SD of TLs, taking as reference the baseline SD. Confirmation of response at a consecutive tumor assessment at least 4 weeks apart was required. The 95% CI was computed using Clopper-Pearson method.
Query!
Timepoint [1]
0
0
Baseline up to withdrawal of consent, loss to follow-up, disease progression, death, or study end (up to approximately 36 months)
Query!
Secondary outcome [2]
0
0
Percentage of Participants With PD (Assessed According to RECIST Version 1.1) or Death Due to Any Cause
Query!
Assessment method [2]
0
0
For TLs, PD was defined as >/=20% relative increase and >/=5 mm of absolute increase in the SD, taking as reference the smallest SD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs.
Query!
Timepoint [2]
0
0
Baseline up to withdrawal of consent, loss to follow-up, disease progression, death, or study end (up to approximately 36 months)
Query!
Secondary outcome [3]
0
0
Progression-free Survival (PFS) Assessed According to RECIST Version 1.1
Query!
Assessment method [3]
0
0
PFS was defined as the time from start of treatment until first documented PD or death from any cause, whichever occurred first. Participants without PD, death, or who were lost to follow-up at the time of analysis were censored at the date of the last tumor assessment when non-progression was documented or at the last date of follow-up, whichever was last. Participants without tumor assessment data after the baseline were censored at baseline unless death occurred before first scheduled tumor assessment. PD was defined as >/=20% relative increase and >/=5 mm of absolute increase in the SD of TLs, taking as reference the smallest SD recorded since treatment started, and/or unequivocal progression of existing non-TLs, or appearance of 1 or more new lesions. Median PFS was estimated using Kaplan-Meier method. The 95% CI was computed using Brookmeyer and Crowley method.
Query!
Timepoint [3]
0
0
Baseline up to withdrawal of consent, loss to follow-up, disease progression, death, or study end (up to approximately 36 months)
Query!
Secondary outcome [4]
0
0
Percentage of Participants Who Died Due to Any Cause
Query!
Assessment method [4]
0
0
Percentage of participants who died due to any cause during the study was reported.
Query!
Timepoint [4]
0
0
Baseline up to withdrawal of consent, loss to follow-up, disease progression, death, or study end (up to approximately 36 months)
Query!
Secondary outcome [5]
0
0
Overall Survival (OS)
Query!
Assessment method [5]
0
0
The OS was defined as the time from the start of treatment until death from any cause. Participants alive at the time of analysis and participants who were lost to follow-up were censored at their last clinical assessment date. Median OS was estimated using Kaplan-Meier method. The 95% CI was computed using Brookmeyer and Crowley method.
Query!
Timepoint [5]
0
0
Baseline up to withdrawal of consent, loss to follow-up, disease progression, death, or study end (up to approximately 36 months)
Query!
Secondary outcome [6]
0
0
Event-free Survival (EFS) Assessed According to RECIST Version 1.1
Query!
Assessment method [6]
0
0
EFS was defined as the time from the start of treatment until the first documented initiation of non-protocol-specified treatment for metastatic breast cancer, PD, or death from any cause, whichever occurred first. Participants without treatment change, PD, death, or who were lost to follow-up at the time of analysis were censored at the date of the last tumor assessment when non-progression was documented or at the last date of follow-up, whichever was last. Participants without tumor assessment after baseline were censored at baseline unless death occurred before first scheduled tumor assessment. PD was defined as >/=20% relative increase and >/=5 mm of absolute increase in the SD of TLs, taking as reference the smallest SD recorded since treatment started, and/or unequivocal progression of existing non-TLs, or appearance of 1 or more new lesions. Median EFS was estimated using Kaplan-Meier method. The 95% CI was computed using Brookmeyer and Crowley method.
Query!
Timepoint [6]
0
0
Baseline up to withdrawal of consent, loss to follow-up, disease progression, death, or study end (up to approximately 36 months)
Query!
Secondary outcome [7]
0
0
Percentage of Participants Who Died During Receiving Second-Line of Treatment
Query!
Assessment method [7]
0
0
Percentage of participants who died from any cause during second-line of treatment was reported.
Query!
Timepoint [7]
0
0
From start of second-line of treatment (any time from baseline up to 35 months) up to death due to any cause or study end (up to approximately 36 months)
Query!
Secondary outcome [8]
0
0
OS During Second-Line of Treatment
Query!
Assessment method [8]
0
0
The OS during second-line therapy was defined as the time from the start of second-line therapy (failure of first-line therapy) until death from any cause. Participants alive at the time of analysis and participants who were lost to follow-up were censored at their last clinical assessment date. Median OS during second-line therapy was estimated using Kaplan-Meier method. The 95% CI was computed using Brookmeyer and Crowley method.
Query!
Timepoint [8]
0
0
From start of second-line of treatment (any time from baseline up to 35 months) up to death due to any cause or study end (up to approximately 36 months)
Query!
Secondary outcome [9]
0
0
Number of Participants Receiving Second-Line Treatment by Treatment Type
Query!
Assessment method [9]
0
0
Second-line anti-cancer treatment was initiated after disease progression on first-line therapy. Number of participants who started second-line of treatment by treatment type was reported. Participants who received combination treatment were counted for each treatment type.
Query!
Timepoint [9]
0
0
Baseline up to approximately 35 months
Query!
Eligibility
Key inclusion criteria
- HER2-positive disease, with an immunohistochemistry score of 3+ or in situ
hybridization (ISH)-positive on primary tumor or metastatic site
- Histologically or cytologically confirmed adenocarcinoma of the breast with metastatic
disease with at least one measurable lesion and/or non-measurable disease according to
RECIST Version 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2 for participants who
will receive paclitaxel or nab-paclitaxel chemotherapy and ECOG 0-1 for participants
who will receive docetaxel chemotherapy
- LVEF of greater than or equal to (>=) 50 percent (%) measured by ECHO or MUGA scan
before the first doses of pertuzumab and trastuzumab
- Previous use of either adjuvant or neoadjuvant anti-HER2 therapy is allowed
- Hormonal therapy will be allowed as per institutional guidelines. Hormonal therapy
cannot be administered in combination with taxane therapy
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Previous systemic non-hormonal anticancer therapy for treatment of mBC
- History of other cancers. Participants with curatively treated carcinoma in situ of
the cervix or basal cell carcinoma and participants with other curatively-treated
cancers who have been disease-free for at least 5 years are eligible. Participants
with previous ductal carcinoma in situ (DCIS) of the breast are also eligible for the
study
- Pregnant or breastfeeding women. Positive serum pregnancy test in women of
childbearing potential, premenopausal or less than 12 months of amenorrhea
post-menopause, within 7 days before the first dose of pertuzumab and trastuzumab
- Current peripheral neuropathy of Grade 3 or greater (National Cancer Institute Common
Terminology Criteria for Adverse Events [NCI CTCAE] Version 4.0)
- Radiographic evidence of central nervous system (CNS) metastases as assessed by
computed tomography (CT) or magnetic resonance imaging (MRI), unless they have been
treated and have been stable for at least 3 months and do not require ongoing
corticosteroid treatment
- Participants with other concurrent serious diseases that may interfere with planned
treatment, including severe pulmonary conditions/illness
- Inadequate organ function
- Serious cardiac illness or medical conditions that would preclude the use of
trastuzumab
- Participants with severe dyspnea at rest or requiring supplementary oxygen therapy
- Concurrent enrollment in another clinical study using an investigational anti-cancer
treatment, within 28 days before the first doses of trastuzumab and pertuzumab
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
5/12/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
4/11/2016
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
50
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,VIC,WA
Query!
Recruitment hospital [1]
0
0
St George Hospital; Cancer Care Centre - Kogarah
Query!
Recruitment hospital [2]
0
0
Port Macquarie Base Hospital - Port Macquarie
Query!
Recruitment hospital [3]
0
0
Newcastle Mater Misericordiae Hospital; Oncology - Waratah
Query!
Recruitment hospital [4]
0
0
Mater Hospital; Cancer Services - South Brisbane
Query!
Recruitment hospital [5]
0
0
Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology - Woolloongabba
Query!
Recruitment hospital [6]
0
0
Lyell McEwin Hospital - Adelaide
Query!
Recruitment hospital [7]
0
0
Launceston General Hospital - Launceston
Query!
Recruitment hospital [8]
0
0
Bendigo Hospital; Oncology - Bendigo
Query!
Recruitment hospital [9]
0
0
Monash Medical Centre; Oncology - Clayton
Query!
Recruitment hospital [10]
0
0
Geelong Hospital; Andrew Love Cancer Centre - Geelong
Query!
Recruitment hospital [11]
0
0
Royal Melbourne Hospital; Hematology and Medical Oncology - Parkville
Query!
Recruitment hospital [12]
0
0
Fiona Stanley Hospital - Murdoch
Query!
Recruitment hospital [13]
0
0
St John of God Murdoch Hospital; Oncology West - Murdoch
Query!
Recruitment postcode(s) [1]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [2]
0
0
2444 - Port Macquarie
Query!
Recruitment postcode(s) [3]
0
0
2298 - Waratah
Query!
Recruitment postcode(s) [4]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [5]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [6]
0
0
5112 - Adelaide
Query!
Recruitment postcode(s) [7]
0
0
7250 - Launceston
Query!
Recruitment postcode(s) [8]
0
0
3550 - Bendigo
Query!
Recruitment postcode(s) [9]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [10]
0
0
3220 - Geelong
Query!
Recruitment postcode(s) [11]
0
0
3052 - Parkville
Query!
Recruitment postcode(s) [12]
0
0
6150 - Murdoch
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This open-label, multicenter, Phase IIIb study will assess the safety, tolerability and
efficacy of a combination therapy of intravenous (IV) pertuzumab (Perjeta), trastuzumab
(Herceptin) SC, and taxane chemotherapy (docetaxel, paclitaxel or nab-paclitaxel) as
first-line therapy in participants with HER2-positive metastatic breast cancer (mBC). All
participants will be treated with 3-week cycles of pertuzumab IV (840 milligrams [mg] first
dose; subsequent doses of 420 mg) and trastuzumab SC (600 milligrams [mg]). The taxane
treatment regimen will be determined by the investigator. Participants will continue therapy
until disease progression, unacceptable toxicity, or the participant withdraws consent,
whichever occurs first.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02019277
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02019277
Download to PDF